Results: 4

1.
Fig. 3

Fig. 3. From: Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer.

Pharmacodynamic effects in paired tumor biopsies. a Data shown represent 24.75 % inhibition in total Ras and 43.65 % inhibition in KRas in Patient 019, a 67-year-old white male with metastases to the liver. b Data shown represent 16.09 % inhibition in total Ras and 42.81 % inhibition in KRas in Patient 023, a 55-year-old white female with metastases to the liver

Daniel Laheru, et al. Invest New Drugs. ;30(6):2391-2399.
2.
Fig. 4

Fig. 4. From: Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer.

Waterfall plot of tumor measurement. Data are shown for patients with both baseline and post-baseline target lesion and CA19-9 measurements. Best response=maximum decrease from baseline in the sum of the longest diameters (SLD) of target lesions; if a decrease from baseline was not seen, the smallest increase from baseline in the SLD of target lesions is presented. [≥25 % increase from baseline in CA19-9 (blue); 25 % change from baseline in CA19-9 (yellow); and ≥25 % decrease from baseline in CA19-9 (red)]

Daniel Laheru, et al. Invest New Drugs. ;30(6):2391-2399.
3.
Fig. 2

Fig. 2. From: Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer.

Average salirasib concentration-time profile. Average plasma concentration-time for all patients after salirasib was administered alone (day 7 or 22; A) or in combination with gemcitabine (day 15 or 8; B). The solid circle (Black Circle), open circle (○), solid triangle (Black Down-Pointing Triangle), and open triangle (White Triangle) represent 200 mg, 400 mg, 600 mg, and 800 mg, respectively. The error bars depict the standard deviation. Concentrations that were BLQ are represented as 0.5 ng/mL (i.e., 1/2 LOQ). Concentrations that were not trough samples were not utilized to calculate the average concentration for that time point

Daniel Laheru, et al. Invest New Drugs. ;30(6):2391-2399.
4.
Fig. 1

Fig. 1. From: Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer.

Efficacy and pharmacodynamic effect of salirasib on PDA PDX. PDX from PDA patients were implanted in athymic mice. Animals with established tumors were treated with the agents as mentioned in the materials and method section. a Anti-tumor effect of salirasib on the tumor growth of fourteen xenografts. Error bars represent standard error of mean (SEM); N=10 tumors per group (5 mice with bilateral flank tumors). Dotted line represents 50 % TGI. Salirasib treatment could reduce tumor volume by 50 % in 410 and 194 xenograft compared to vehicle treated animals. b Growth curves of A6L and 265 xenografts treated with vehicle, salirasib, GEM or combination of GEM and Salirasib. c Immunoblots showing that a combination of GEM and Salirasib treatment inhibits the expression of K-Ras, p-Akt, p-MEK (blots in side the green rectangle). C-PARP expression was up-regulated in the tumors of GEM or combination of GEM and salirasib treatment as compared to vehicle or salirasib treated tumors. Two separate tumors from the vehicle, salirasib, GEM and GEM plus salirasib treatment were homogenized. Lyates were resolved in SDS-PAGE and probed with specific antibodies against indicated proteins. β-actin was used as a loading control

Daniel Laheru, et al. Invest New Drugs. ;30(6):2391-2399.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk